(Q39335358)

English

A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS.

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS. (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

0 references

0 references

1 reference

based on heuristic

inferred from title

author name string

Richard Krause

1

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Vanessa Ameen

2

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Susan H Gordon

3

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Marquita West

4

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Amy T Heath

5

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Teresa Perschy

6

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Eric G Carter

7

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

language of work or name

0 references

publication date

17 May 2007

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

The American Journal of Gastroenterology

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

102

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

1709-1719

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Functional bowel disorders

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01282.X

21 January 2018

Gender, age, society, culture, and the patient's perspective in the functional gastrointestinal disorders

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01282.X

21 January 2018

The impact of irritable bowel syndrome on health-related quality of life

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01282.X

21 January 2018

Health-related quality of life and health care costs in severe, refractory irritable bowel syndrome.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01282.X

21 January 2018

Costs of irritable bowel syndrome in the UK and US.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01282.X

21 January 2018

Irritable bowel syndrome: a technical review for practice guideline development

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01282.X

21 January 2018

Irritable bowel syndrome in general practice: prevalence, characteristics, and referral

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01282.X

21 January 2018

A national survey of practice patterns of gastroenterologists with comparison to the past two decades

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01282.X

21 January 2018

Alosetron in irritable bowel syndrome: strategies for its use in a common gastrointestinal disorder

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01282.X

21 January 2018

Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01282.X

21 January 2018

Effect of alosetron on bowel urgency and global symptoms in women with severe, diarrhea-predominant irritable bowel syndrome: analysis of two controlled trials

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01282.X

21 January 2018

Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01282.X

21 January 2018

A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01282.X

21 January 2018

Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01282.X

21 January 2018

Patient satisfaction with alosetron for the treatment of women with diarrhea-predominant irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01282.X

21 January 2018

Alosetron improves quality of life in women with diarrhea-predominant irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01282.X

21 January 2018

Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01282.X

21 January 2018

Occurrence of colon ischemia in relation to irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01282.X

21 January 2018

Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01282.X

21 January 2018

Irritable bowel syndrome: toward an understanding of severity

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01282.X

21 January 2018

Use of a novel electronic data collection system in multicenter studies of irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01282.X

21 January 2018

Validation of irritable bowel syndrome Global Improvement Scale: an integrated symptom end point for assessing treatment efficacy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01282.X

21 January 2018

Gender-related differences in slowing colonic transit by a 5-HT3 antagonist in subjects with diarrhea-predominant irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01282.X

21 January 2018

Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01282.X

21 January 2018

Condition-specific deactivation of brain regions by 5-HT3 receptor antagonist Alosetron

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01282.X

21 January 2018

The effect of the 5-HT3 receptor antagonist, alosetron, on brain responses to visceral stimulation in irritable bowel syndrome patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01282.X

21 January 2018

Reports of "satisfactory relief" by IBS patients receiving usual medical care are confounded by baseline symptom severity and do not accurately reflect symptom improvement

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01282.X

21 January 2018

Irritable bowel syndrome clinical trial design: future needs

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01282.X

21 January 2018

Design of treatment trials for functional gastrointestinal disorders

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01282.X

21 January 2018

Identifiers

10.1111/J.1572-0241.2007.01282.X

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39335358&oldid=1509008042"